Trends in drug repurposing for chronic hepatitis-B infection: Bibliometric-based approach 1990-2024

Chronic hepatitis B (CHB) infection is still a world problem today, especially in the developing countries. Until now, treatment related to CHB is still being continuously pursued using a variety of the latest approaches. One of today’s scientific efforts that can accelerate drug discovery for CHB is by using the concept of drug repurposing or drug repositioning. Our research drug trends using a drug repurposing approach for CHB from 1990-2024. To find the related data, we used some words include “drug repurposing, drug repositioning, drug retasking, drug re- profiling, drug recycling, drug redirection and therapeutic switching”. The study trends we analysed were from 1990-2024, with details of 259 documents originating from 189 journals. The types of articles nominated included 134 original articles and 105 documents review articles. The most dominant drug repurposing study trend in 2021 (46 documents), subsequently followed by 2022 (39 documents), 2020 (33 documents) and 2023 (24 documents). The countries with the highest level of paper citations related drug repurposing are the USA and Germany. our findings show a trend in studies related to the reuse of drugs for CHB in the latest of current decade showing serious focus given by scientists who are concerned about Hepatitis B